PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Anti-Keratin-18 & 19 Antibodies - AnaSpec has introduced two new catalog antibodies: Anti-Keratin-18 and Anti-Keratin-19
AnaSpec Introduces Anti-Keratin-18 & 19 Antibodies

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2007/10/23 - AnaSpec has introduced two new catalog antibodies: Anti-Keratin-18 and Anti-Keratin-19.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Intermediate filaments (IFs), together with actin microfilaments and tubulin microtubules, comprise the three major cytoskeletal networks that are found in most eukaryotic cells.1 Keratins, which are the largest IF protein subgroup, can be divided into the acidic type I (K9-K20) and basic type II (K1-K8) keratins.2 Typically, epithelial cells express at least one of each type, and the proteins exist in the cells as noncovalent obligate heteropolymers. Keratin networks are highly dynamic and reorganized during cell differentiation, mitosis and apoptosis, and also play important cytoprotective and structural support roles for the cell.3,4 During apoptosis, the epithelial keratins 18/19 undergo caspase-mediated proteolysis, leading to the disassembly of the nuclear envelope and cytoplasmic IF networks.5 K18 and K19 undergo caspase-cleavage at the conserved Asp237 in their rod domains.5 In contrast to other type I keratins, K18 is unique in that it includes another caspase-cleavage site at Asp396 of the carboxy-terminal domain.6

Anti-Keratin-18
Rabbit anti-human K18 (IN-2) polyclonal antibody was raised against a synthetic peptide corresponding to an internal sequence of human keratin-18. This epitope affinity purified rabbit polyclonal antibody reacts predominantly with human keratin-18. Western blot using HT29 cell lysate from human colonic carcinoma shows a 49 kDa immunoreactive protein. Human, mouse, and monkey reactive. Predicted to detect dog, bovine, and frog keratin -18.

Anti-Keratin-19
Rabbit anti-human K19 (IN) polyclonal antibody was raised against a synthetic peptide corresponding to an internal sequence of human keratin-19. This epitope affinity purified rabbit polyclonal antibody reacts predominantly with human keratin-19. Western blot using HT29 cell lysate from human colonic carcinoma shows a ~45 kDa immunoreactive protein. Human, mouse, chimpanzee, and monkey reactive. Predicted to detect rat and bovine keratin-19.

About AnaSpec, Inc.

AnaSpec, Inc. (anaspec.com) is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.

References:
1. Ku, NO. et al. Am. J. Physiol. 277, G1108 (1999)
2. Schweizer, J. et al. J. Cell. Biol. 174, 169 (2006)
3. Omary, MB. et al. et al. Trends Biochem. Sci. 31, 383 (2006)
4. Omary, MB. et al. N. Engl. J. Med. 351, 2087 (2004)
5. Ku, NO. et al. J. Biol. Chem. 272, 33197 (1997)
6. Ku, NO. and MB. Omary, J. Biol. Chem. 276, 26792 (2001)

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Anti-Keratin-18 & 19 Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
1-408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)